JAJuan J. Aragón

Juan J. Aragón

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan J. Aragón has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Oscar H. Martinez-Costa

    Departamento de Bioquímica de la UAM and Instituto de Investigaciones Biomédicas Alberto Sols UAM-CSIC, Facultad de Medicina de la Universidad Autónoma de Madrid, 28029 Madrid, Spain

    6 shared publications
  • Cristina Ferreras

    Departamento de Bioquímica and Instituto de Investigaciones Biomédicas Alberto Sols Universidad Autónoma de Madrid–CSIC, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain

    4 shared publications
  • Valentina Sánchez

    Departamento de Bioquímica and Instituto de Investigaciones Biomédicas Alberto Sols, Facultad de Medicina de la Universidad Autónoma de Madrid Universidad Autónoma de Madrid‐Consejo Superior de Investigaciones Científicas Madrid Spain

    4 shared publications
  • Eloy D. Hernández

    Departamento de Bioquimica de la Universidad Autonoma de Madrid and Instituto de Investigaciones Biomedicas Alberto Sols Universidad Autonoma de Madrid-Consejo Superior de Investigaciones Cientificas, Facultad de Medicina de la Universidad Autonoma de Madrid, 28029 Madrid, Spain

    3 shared publications
  • Alfonso Fernández-Mayoralas

    Instituto de Química Orgánica General, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain

    2 shared publications
  • Carmen Hermida

    Departamento de Bioquímica and Instituto de Investigaciones Biomédicas Alberto Sols, Facultad de Medicina de la Universidad Autónoma de Madrid, Universidad Autónoma de Madrid-Consejo Superior de Investigaciones Científicas, Madrid, Spain; Venter Pharma SL, Madrid, Spain

    2 shared publications

Latest Publications

  • Open Access

    Improvement and Validation of d‐Xylose Determination in Urine and Serum as a New Tool for the Noninvasive Evaluation of Lactase Activity in Humans

    by Carmen Hermida, Oscar H. Martínez‐Costa, Guillermo Corrales, Cristina Teruel, Valentina Sánchez, José J. Sánchez, Dolores Sarrión, María J. Ariza, Rosa Codoceo, Idoya Calvo, et al.

    Background: The phloroglucinol assay is the current method for d‐xylose determination in urine/plasma/serum. However, its sensitivity is limited when low amounts of d‐xylose are to be measured, such as in the noninvasive evaluation of intestinal lactase with 4‐galactosylxylose (gaxilose). An improved assay was therefore needed.Methods: We developed and validated a modified version of the phloroglucinol‐based assay for quantification of d‐xylose in urine/serum samples. A method for gaxilose determination by gas chromatography (GC) was also optimized.Results: Linearity ranged from 0.125 to 5.0 mg/l (5–200 mg/l in original sample). Accuracy at LOQ (0.125 mg/l) was 0.97/2.49% in spiked urine/serum; for other quality controls (QC), it was <1.27%. Intra‐ and interassay precision at LOQ were 6.02% and 6.45% for urine, and 8.86% and 10.00%, respectively, for serum; for other QC, precision was <2.15%. Linearity of gaxilose determination by GC was 3.90–195.17 for urine and 9.75–195.17 mg/l for serum with acceptable sensitivity and reproducibility. The method proved adequate for the d‐xylose determination in healthy and hypolactasic subjects after oral administration of gaxilose.Conclusions: The modified method provides high sensitivity and robustness for d‐xylose quantification in urine/serum for routine clinical use especially in the noninvasive diagnosis of intestinal lactase deficiency with the gaxilose test.


  • Phase I and Phase IB Clinical Trials for the Noninvasive Evaluation of Intestinal Lactase With 4-Galactosylxylose (Gaxilose)

    by Carmen Hermida, Pedro Guerra, Oscar H. Martínez-Costa, Valentina Sánchez, José J. Sánchez, Jesús Solera, Alfonso Fernández-Mayoralas, Rosa Codoceo, Jesús Frías, Juan J. Aragón

    Goals and Background: Hypolactasia is widespread, yet reliable diagnostic tests are lacking. A new test based on oral administration of 4-galactosylxylose (gaxilose) and urine or serum measurement of d-xylose after cleavage by intestinal lactase is under clinical development. We investigated the optimal dose of gaxilose and calculate cutoff values of d-xylose for that dose. Study: In the randomized, dose-finding, phase I study, urine and serum pharmacokinetics of d-xylose were determined after oral administration of 6 ascending doses of gaxilose (and placebo) to 12 healthy adult volunteers. In the open, parallel, phase Ib study, 30 volunteers received the doses established for the urine and blood tests and d-xylose was measured. Cutoff values were calculated as 1.96xSD below the mean value. Safety was assessed through reporting of adverse events. Results: Gaxilose administration showed a progressive, dose-dependent increase in d-xylose in urine and serum. An optimal gaxilose dose of 0.45 g and urine collection periods of 4 and 5 hours were selected for further studies. For the blood test, a 2.7 g dose was selected and C-max measured at 90 minutes. The calculated cutoff values of d-xylose for normal lactase activity were 27.58 and 37.87 mg for the 4- and 5-hour urine tests, respectively, and 0.97 mg/dL for the blood test. There were no treatment-related adverse events. Conclusions: The methodology described provides a simple, safe test for the evaluation of lactase activity in vivo. Further evaluation of the test as a noninvasive diagnosis of hypolactasia is ongoing in patients with lactose intolerance.


  • Distinct functional roles of the two terminal halves of eukaryotic phosphofructokinase

    by Oscar H. Martínez-Costa, Valentina Sánchez, Antonio Lázaro, Eloy D. Hernández, Keith Tornheim, Juan J. Aragón

    Eukaryotic PFK (phosphofructokinase), a key regulatory enzyme in glycolysis, has homologous N- and C-terminal domains thought to result from duplication, fusion and divergence of an ancestral prokaryotic gene. It has been suggested that both the active site and the Fru-2,6-P2 (fructose 2,6-bisphosphate) allosteric site are formed by opposing N- and C-termini of subunits orientated antiparallel in a dimer. In contrast, we show in the present study that in fact the N-terminal halves form the active site, since expression of the N-terminal half of the enzymes from Dictyostelium discoideum and human muscle in PFK-deficient yeast restored growth on glucose. However, the N-terminus alone was not stable in vitro. The C-terminus is not catalytic, but is needed for stability of the enzyme, as is the connecting peptide that normally joins the two domains (here included in the N-terminus). Co-expression of homologous, but not heterologous, N- and C-termini yielded stable fully active enzymes in vitro with sizes and kinetic properties similar to those of the wild-type tetrameric enzymes. This indicates that the separately translated domains can fold sufficiently well to bind to each other, that such binding of complementary domains is stable and that the alignment is sufficiently accurate and tight as to preserve metabolite binding sites and allosteric interactions.


  • Electron microscopy analysis of mammalian phosphofructokinase reveals an unusual 3-dimensional structure with significant implications for enzyme function

    by Ignacio Arechaga, Oscar H. Martínez-Costa, Cristina Ferreras, José L. Carrascosa, Juan J. Aragón

    Phosphofructokinase is a sophisticated allosteric enzyme that is fundamental for the control of glycolysis. The structure of the bacterial enzyme is well characterized. However, little is known about the structural organization of the more complex enzyme from mammals. We have obtained the structure of human muscle phosphofructokinase in the presence of fructose 6-phosphate at a resolution of 1.8 nm by electron microscopy (EM). Particles of the tetrameric enzyme corresponded to an elongated molecule (14.5×9 nm) arranged into 2 dimeric subdomains. Image analysis and 3-dimensional reconstruction showed the presence of a prominent channel in one of the dimers but not in the opposite one, revealing that they are in greatly different conformations. Fitting of bacterial structures into the EM model suggested disruption of the fructose 6-phosphate catalytic and the fructose 2,6-bisphophate allosteric sites in the cavity-containing dimer. Therefore, the reported structure might have major implications for the function of mammalian phosphofructokinase.—Arechaga, I., Martínez-Costa, O. H., Ferreras, C., Carrascosa, J. L., Aragón, J. J. Electron microscopy analysis of mammalian phosphofructokinase reveals an unusual 3-dimensional structure with significant implications for enzyme function.


  • Open Access

    Electron microscopy analysis of mammalian phosphofructokinase reveals an unusual 3‐dimensional structure with significant implications for enzyme function

    by Ignacio Arechaga, Oscar H. Martínez-Costa, Cristina Ferreras, José L. Carrascosa, Juan J. Aragón

    Phosphofructokinase is a sophisticated allosteric enzyme that is fundamental for the control of glycolysis. The structure of the bacterial enzyme is well characterized. However, little is known about the structural organization of the more complex enzyme from mammals. We have obtained the structure of human muscle phosphofructokinase in the presence of fructose 6‐phosphate at a resolution of 1.8 nm by electron microscopy (EM). Particles of the tetrameric enzyme corresponded to an elongated molecule (14.5 ×9nm) arranged into 2 dimeric subdomains. Image analysis and 3‐dimensional reconstruction showed the presence of a prominent channel in one of the dimers but not in the opposite one, revealing that they are in greatly different conformations. Fitting of bacterial structures into the EM model suggested disruption of the fructose 6‐phosphate catalytic and the fructose 2,6‐bisphophate allosteric sites in the cavity‐containing dimer. Therefore, the reported structure might have major implications for the function of mammalian phosphofructoki‐nase.—Arechaga, I., Martínez‐Costa, O. H., Ferreras, C., Carrascosa, J. L., Aragon, J. J. Electron microscopy analysis of mammalian phosphofructokinase reveals an unusual 3‐dimensional structure with significant implications for enzyme function. FASEB J. 24, 4960–4968 (2010). www.fasebj.org


  • Organization and Structural Features of Phosphofructokinase and other Glycolytic Enzymes to Meet their Role in Energy Metabolism

    by Juan J. Aragón, Cristina Ferreras, Cristina Sánchez, Valentina Sánchez, Eloy D. Hernández, Carmen Hermida, Cristina Adan, Rafael Garesse, Oscar H. Martínez-Costa